As of 2025-07-16, the Intrinsic Value of Balaxi Pharmaceuticals Ltd (BALAXI.NS) is 177.00 INR. This BALAXI.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 48.89 INR, the upside of Balaxi Pharmaceuticals Ltd is 262.00%.
The range of the Intrinsic Value is 152.11 - 213.39 INR
Based on its market price of 48.89 INR and our intrinsic valuation, Balaxi Pharmaceuticals Ltd (BALAXI.NS) is undervalued by 262.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 152.11 - 213.39 | 177.00 | 262.0% |
| DCF (Growth 10y) | 179.82 - 252.16 | 209.36 | 328.2% |
| DCF (EBITDA 5y) | 172.79 - 258.08 | 212.59 | 334.8% |
| DCF (EBITDA 10y) | 189.11 - 277.55 | 228.43 | 367.2% |
| Fair Value | 569.02 - 569.02 | 569.02 | 1,063.89% |
| P/E | 246.73 - 345.61 | 278.04 | 468.7% |
| EV/EBITDA | 114.39 - 317.74 | 211.50 | 332.6% |
| EPV | 250.14 - 336.40 | 293.27 | 499.9% |
| DDM - Stable | 80.18 - 150.33 | 115.26 | 135.7% |
| DDM - Multi | 77.49 - 123.74 | 96.09 | 96.5% |
| Market Cap (mil) | 538.50 |
| Beta | 1.17 |
| Outstanding shares (mil) | 11.01 |
| Enterprise Value (mil) | 678.75 |
| Market risk premium | 8.31% |
| Cost of Equity | 17.25% |
| Cost of Debt | 8.70% |
| WACC | 12.35% |